Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNUS-2 ianalumab phase 3 trial in active Sjögren's syndrome
2024-511068-10-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in Sjögren's syndrome (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in ESSDAI score at week 48. Started Aug 2022; status: completed.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2024-511068-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511068-10-00.